Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 20;3(6):498-502.
doi: 10.1111/j.2040-1124.2012.00220.x.

Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Takafumi Senmaru  1 , Michiaki Fukui  1 , Kanae Kobayashi  1 , Hiroya Iwase  1 , Shinobu Inada  1 , Hiroshi Okada  1 , Mai Asano  1 , Masahiro Yamazaki  1 , Goji Hasegawa  1 , Naoto Nakamura  1 , Masahiro Iwasaki  2 , Daisuke Yabe  3 , Takeshi Kurose  4 , Yutaka Seino  3
Affiliations

Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Takafumi Senmaru et al. J Diabetes Investig. .

Abstract

Aims/Introduction: Eicosapentaenoic acid (EPA) stimulates glucagon-like peptide-1 (GLP-1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl-peptidase IV (DPP-4) inhibitor in patients with type 2 diabetes.

Materials and methods: Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP-4 inhibitor as a monotherapy or as an add-on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP-4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs.

Results: Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP-4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = -0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = -0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c.

Conclusions: DPP-4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00220.x , 2012).

Keywords: Dipeptidyl‐peptidase IV inhibitor; Eicosapentaenoic acid; Glucagon‐like peptide‐1.

PubMed Disclaimer

References

    1. Seino Y, Fukushima M, Yabe D. GIP and GLP‐1, the two incretin hormons: similarities and differences. J Diabetes Invest 2010; 1: 9–23 - PMC - PubMed
    1. Ahren B. GLP‐1 and extra‐islet effects. Horm Metab Res 2004; 36: 842–845 - PubMed
    1. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon‐like peptide‐1 (GLP‐1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304–311 - PubMed
    1. Toft‐Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon‐like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137–1143 - PubMed
    1. Brubaker PL. The glucagon‐like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006; 1070: 10–26 - PubMed